Particle.news
Download on the App Store
7 ARTICLES
·
last wk.

White House Adds 9 Pharma Deals, Extending Drug-Price Pacts to 14 Manufacturers

The voluntary pacts trade pricing concessions for investment pledges, tariff relief, with a new TrumpRx channel slated for early 2026.

Donald Trump departs after delivering remarks on lowering prescription drug prices at an event in the Roosevelt Room of the White House on December 19, 2025, in Washington, D.C.
Image
Pharmacist recommends medicines to customers. Asking the questions of medication. Professional Asian male pharmacist giving prescription medications to female patient customers at drugstore shelves.
Image

Overview

  • Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novartis and Sanofi joined earlier signers, bringing MFN-style pricing agreements to 14 of 17 targeted drugmakers.
  • The deals align Medicaid prices for new drugs with the lowest paid in other wealthy countries, with the White House projecting billions in savings for state programs.
  • Select medicines will be sold at steep cash-pay discounts through TrumpRx.gov, slated for early 2026, with examples including Merck’s Januvia at $100 and Amgen’s Repatha at $239 when purchased directly.
  • Manufacturers pledged more than $150 billion for U.S. R&D and production, will donate to an emergency API reserve, and received three-year exemptions from potential drug tariffs.
  • Advocates and some lawmakers question the voluntary, partly undisclosed terms and the impact on insured patients, and note that some named drugs are near patent expiry; AbbVie, Johnson & Johnson and Regeneron have not signed.